Plasmacytoma in patients with multiple myeloma: morphology and immunohistochemistry

• Published in: BMC cancer Vol. 20; no. 1; p. 346
• Main Authors: Firsova, Maiia V, Mendeleeva, Larisa P, Kovrigina, Alla M, Solovev, Maxim V, Savchenko, Valery G
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 22.04.2020; BioMed Central; BMC
• Subjects: Adult; Aged; Biopsy; Bone growth; Bone marrow; c-Myc protein; Care and treatment; CD 166; CD56; CD56 antigen; Cell adhesion & migration; Cell growth; Cell morphology; Chemokines; CXCR4 protein; Cytology; Extramedullary disease; Female; Follow-Up Studies; Humans; Immunohistochemistry; Immunohistochemistry - methods; Ki-67; Lymphomas; Male; Medical research; Middle Aged; Morphology; Multiple myeloma; Multiple Myeloma - pathology; Myc protein; Pathogenesis; Plasma; Plasma cells; Plasmacytoma; Plasmacytoma - pathology; Prognosis; Proteins; Studies; Tumors; Young Adult; CD 166; Immunohistochemistry; Ki-67; Extramedullary disease; Multiple myeloma; C-MYC; CXCR4; Plasmacytoma; CD56
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-020-06870-w

To study the histological structure and immunohistochemical (IHC) parameters of the plasmacytoma tumour substrate in patients with multiple myeloma (MM). The study included 21 patients (10 men/11 women) aged 23 to 73 years old with newly diagnosed MM complicated by plasmacytoma. Bone plasmacytoma was diagnosed in 14 patients, and extramedullary plasmacytoma was diagnosed in 7 patients. Plasmacytoma tissue specimens were examined using a LEICA DM4000B microscope. Anti-CD56, anti-CD166, anti-CXCR4, anti-Ki-67, and anti-c-MYC antibodies were used for IHC study of plasmacytoma biopsies. When comparing the morphology of bone and extramedullary plasmacytoma, no significant differences were revealed; however, the substrate of extramedullary plasmacytoma was more often represented by tumour cells with an immature morphology than was the bone plasmacytoma substrate (57.1% vs. 28.6%, respectively). We revealed a significant difference in the expression of CD166 between bone and extramedullary plasmacytoma. The mean values ​​of CD166 expression in bone plasmacytoma cells were significantly higher (36.29 ± 7.61% versus 9.57 ± 8.46%, respectively; p = 0.033) than those in extramedullary plasmacytoma cells. We noticed that in extramedullary plasmacytoma cells, there were higher values for the Ki-67 index than in bone plasmacytoma cells, and this result was independent of cell morphology. The mechanisms involved in the dissemination of tumour plasma cells are currently unexplored. Even in such a small sample, some differences in expression could be identified, which may indicate that different mechanisms lead to the formation of bone and extramedullary plasmacytomas. Specifically, the expression of CD166 in extramedullary plasmacytoma cells was almost 4 times lower than that in bone plasmacytoma cells, which may indicate the involvement of CD166 in the mechanisms of bone destruction. The proliferative activity of extramedullary plasmacytoma cells was shown to be higher than that of bone plasmacytoma cells.